TY - JOUR
T1 - Thermal immuno-nanomedicine in cancer
AU - Yang, Zhe
AU - Gao, Di
AU - Zhao, Jing
AU - Yang, Gaojie
AU - Guo, Ming
AU - Wang, Ying
AU - Ren, Xuechun
AU - Kim, Jong Seung
AU - Jin, Lin
AU - Tian, Zhongmin
AU - Zhang, Xingcai
N1 - Funding Information:
X.Z., G.Y. and M.G. acknowledge support from Harvard/MIT. Z.Y. acknowledges research support from the National Natural Science Foundation of China (51703178), China Postdoctoral Science Foundation (2019M663742), Natural Science Foundation of Shaanxi Province (2022JM183), Natural Science Foundation of Zhejiang Province (LWY20H180002), Shaanxi Provincial Key R&D Program (2022SF-342) and Fundamental Research Funds for the Central Universities (xpt012022030, xtr052022012). D.G. acknowledges research support from the National Natural Science Foundation of China (51903203), China Postdoctoral Science Foundation (2019M653661) and Fundamental Research Funds for the Central Universities (xzy012022037). L.J. acknowledges research support from The Program of Innovative Research Team (in Science and Technology) University of Henan Province (23IRTSTHN008) and the Zhongyuan Thousand Talents Plan. Z.T. acknowledges research support from the National Natural Science Foundation of China (82070751).
Publisher Copyright:
© 2023, Springer Nature Limited.
PY - 2023/2
Y1 - 2023/2
N2 - Immunotherapy has revolutionized the treatment of patients with cancer. However, promoting antitumour immunity in patients with tumours that are resistant to these therapies remains a challenge. Thermal therapies provide a promising immune-adjuvant strategy for use with immunotherapy, mostly owing to the capacity to reprogramme the tumour microenvironment through induction of immunogenic cell death, which also promotes the recruitment of endogenous immune cells. Thus, thermal immunotherapeutic strategies for various cancers are an area of considerable research interest. In this Review, we describe the role of the various thermal therapies and provide an update on attempts to combine these with immunotherapies in clinical trials. We also provide an overview of the preclinical development of various thermal immuno-nanomedicines, which are capable of combining thermal therapies with various immunotherapy strategies in a single therapeutic platform. Finally, we discuss the challenges associated with the clinical translation of thermal immuno-nanomedicines and emphasize the importance of multidisciplinary and inter-professional collaboration to facilitate the optimal translation of this technology from bench to bedside.
AB - Immunotherapy has revolutionized the treatment of patients with cancer. However, promoting antitumour immunity in patients with tumours that are resistant to these therapies remains a challenge. Thermal therapies provide a promising immune-adjuvant strategy for use with immunotherapy, mostly owing to the capacity to reprogramme the tumour microenvironment through induction of immunogenic cell death, which also promotes the recruitment of endogenous immune cells. Thus, thermal immunotherapeutic strategies for various cancers are an area of considerable research interest. In this Review, we describe the role of the various thermal therapies and provide an update on attempts to combine these with immunotherapies in clinical trials. We also provide an overview of the preclinical development of various thermal immuno-nanomedicines, which are capable of combining thermal therapies with various immunotherapy strategies in a single therapeutic platform. Finally, we discuss the challenges associated with the clinical translation of thermal immuno-nanomedicines and emphasize the importance of multidisciplinary and inter-professional collaboration to facilitate the optimal translation of this technology from bench to bedside.
UR - http://www.scopus.com/inward/record.url?scp=85145751960&partnerID=8YFLogxK
U2 - 10.1038/s41571-022-00717-y
DO - 10.1038/s41571-022-00717-y
M3 - Review article
C2 - 36604531
AN - SCOPUS:85145751960
SN - 1759-4774
VL - 20
SP - 116
EP - 134
JO - Nature Reviews Clinical Oncology
JF - Nature Reviews Clinical Oncology
IS - 2
ER -